Stage 4 Melanoma Survival Statistics and What You Need to Know
In this article
Stage 4 Melanoma: Survival Statistics and What You Need to Know
Melanoma is a skin cancer that develops from pigment cells (melanocytes), which give skin its color. Stage 4 (metastatic) melanoma means that the disease has spread elsewhere in the body, such as the lungs, liver, brain, distant skin sites or distant lymph nodes. Fifteen years ago, median survival in stage 4 melanoma was less than a year. Today, immunotherapy and targeted treatments have fundamentally changed the picture: in one of the largest studies, among patients receiving dual immunotherapy, 43% were alive after 10 years. In this article, we explain current survival statistics, how to interpret them, treatment options and the situation in Türkiye.
- United States data (SEER, 2016-2022): 5-year relative survival for melanoma with distant spread is 34%. Across all stages, it is 94,7%.
- Long-term immunotherapy data: With nivolumab + ipilimumab in CheckMate 067, 10-year survival was 43%, and median survival was approximately 6 years (71,9 months).
- Lasting control is possible: 96% of patients whose disease had not progressed at year three had not died from melanoma by year 10.
- BRAF mutation: Present in approximately half of patients; in these patients, starting treatment with immunotherapy also provided longer survival in studies.
- New options: Tumor-derived T-cell therapy (lifileucel, 2024) and the oncolytic virus RP1 (August 2026) were approved for use after immunotherapy.
- Türkiye: Approximately 1.700 new melanoma cases are diagnosed annually. Immunotherapy and BRAF/MEK drugs are covered by SGK reimbursement under certain conditions.
Melanoma can develop anywhere on the body; it is more common on the trunk, chest and back in men and on the legs in women. The head and neck are also common sites. We explain symptoms, stages and the general treatment approach in our malignant melanoma guide in detail. After lung and breast cancer, advanced melanoma is the third most common cause of brain metastasis.
This article updates a piece first published on our website in 2019. Both statistics and treatment options have changed substantially since then. Figures such as "5-year survival in stage 4 melanoma is 10-25%," still common in older sources, do not reflect the reality of patients being treated today.
How Should Melanoma Survival Statistics Be Interpreted?
The most commonly used measure in cancer is 5-year survival, the percentage of patients alive at least 5 years after diagnosis. The United States National Cancer Institute's SEER database uses relative survival : it compares survival in melanoma patients with that of the general population of the same age and sex. This excludes deaths due to other causes, such as heart disease.
Keep three points in mind when interpreting these figures:
- They look backward: 5-year survival reported today is based on patients diagnosed 5-10 years ago and does not fully reflect the newest treatments.
- They are averages: The calculations include very old people, those unable to receive treatment and those with other serious illnesses. They do not predict an individual patient's course.
- Study data differ from population data: Clinical trial participants are selected patients in good general condition, so study results are generally better than population figures.
United States Population Data (SEER)
| Extent at Diagnosis | Proportion of Patients | 5-Year Relative Survival |
|---|---|---|
| Localized (skin only) | 77% | 100% |
| Regional (nearby lymph nodes or surrounding tissue) | 10% | 76% |
| Distant (metastatic, stage 4) | 5% | 34% |
| All stages | — | 94,7% |
Source: SEER, diagnoses in 2016-2022. Approximately 112.000 new melanoma diagnoses and 8.510 melanoma deaths are expected in the United States in 2026. Most melanomas are detected early while confined to the skin, explaining the high overall survival.
Survival by Stage (AJCC 8th Edition)
The American Joint Committee on Cancer's (AJCC) 8th-edition staging system, published in 2017, reported melanoma-specific survival by stage using data from more than 46.000 patients. These figures count only deaths due to melanoma:
| Stage | 5-Year | 10-Year |
|---|---|---|
| IA | 99% | 98% |
| IB | 97% | 94% |
| IIA | 94% | 88% |
| IIB | 87% | 82% |
| IIC | 82% | 75% |
| IIIA | 93% | 88% |
| IIIB | 83% | 77% |
| IIIC | 69% | 60% |
| IIID | 32% | 24% |
| IV | AJCC 8 does not provide survival rates for stage IV (see below) | |
A noteworthy point: Stage IIIA patients have better survival than stage IIC patients. In other words, a thin melanoma with microscopic lymph node spread can have a better course than a thick, ulcerated melanoma without lymph node spread. These data come from patients treated before adjuvant (postoperative) immunotherapy became widespread. We discuss the role of sentinel lymph node biopsy in staging in this article, and treatment of stage 3 melanoma in this article .
Stage 4 Melanoma Subgroups (M1a-M1d)
In AJCC 8th-edition staging, stage 4 melanoma is divided into four subgroups according to the site of distant spread, and blood LDH enzyme levels are added to each group. High LDH is an important prognostic indicator suggesting more extensive and aggressive disease.
Figure 1 · M Subgroups in Stage 4 Melanoma
The most distant site of spread and the LDH level are assessed together.
Main Factors Affecting the Outlook
- LDH level: Normal LDH is one of the most consistent indicators of a better course. For example, in a long-term analysis of patients receiving BRAF/MEK treatment, 5-year survival was 55% among those with normal LDH and disease in fewer than 3 organs, versus 34% overall.
- Sites and number of metastases: Spread confined to the skin and lymph nodes generally has a better outlook than spread to internal organs or the brain.
- Brain metastasis: Historically among the worst prognostic factors; today, long-term control is possible with dual immunotherapy in asymptomatic brain metastases (see below).
- General condition: Patients able to perform daily activities benefit more from treatment.
- Treatment response: Long-term survival is significantly higher in patients achieving a complete response that lasts for years.
The Treatment Revolution: Changes in Survival
Until 2011, no effective treatment existed for stage 4 melanoma; chemotherapy responses were infrequent and short-lived. After 2011, two different treatment approaches, immune checkpoint inhibitors and BRAF/MEK inhibitors, made melanoma one of the fastest-advancing areas in oncology. Immune checkpoint inhibitors, now used for many cancers, were first approved in melanoma.
Long-Term Results of Major Studies
| Treatment (Study) | Median Survival | Long-Term Survival |
|---|---|---|
| Nivolumab + ipilimumab (CheckMate 067) | 71,9 months | 43% at 10 years |
| Nivolumab (CheckMate 067) | 36,9 months | 37% at 10 years |
| Pembrolizumab (KEYNOTE-006) | 32,7 months | 34% at 10 years |
| Nivolumab + relatlimab (RELATIVITY-047) | 54,8 months | 5-year rate not disclosed |
| Dabrafenib + trametinib (COMBI-d/v) | 25,9 months | 34% at 5 years |
| Ipilimumab alone (CheckMate 067) | 19,9 months | 19% at 10 years |
The most encouraging aspect of these data is that long-term control is now a real possibility. In CheckMate 067, patients alive without disease progression at year 3 had 96% melanoma-specific survival at year 10; in other words, melanoma did not become a problem again for the vast majority. The same study reported that a substantial proportion in the dual immunotherapy arm needed no further cancer treatment for 10 years.
Figure 2 · The Same Disease, Three Different Figures
Knowing which figure describes which patient group is key to interpreting statistics correctly.
How Is Stage 4 Melanoma Treated?
The main treatments for advanced melanoma are intravenously administered (and now, for some drugs, subcutaneous) immunotherapies and orally taken targeted drugs. Chemotherapy has limited effectiveness in melanoma and is now used only when other options are exhausted. Radiotherapy plays an important role in controlling pain and symptoms, particularly from brain and bone metastases. Surgery may also be part of treatment in selected patients with a limited number of metastases.
Figure 3 · General Treatment Approach to Advanced Melanoma
Treatment is individualized according to BRAF status, disease extent, brain metastases and general condition.
Immunotherapy
- Dual immunotherapy (nivolumab + ipilimumab): The regimen with the strongest long-term results. It is the most effective, but serious side effects are more common; it is preferred for patients in good general condition.
- Nivolumab + relatlimab: A single-vial combination targeting two different checkpoints (PD-1 and LAG-3). In the 5-year RELATIVITY-047 analysis, median survival was 54,8 months versus 33,2 months with nivolumab alone (HR 0,78). Serious side effects are less frequent than with nivolumab + ipilimumab. We discuss its situation in our country in our Opdualag article .
- Anti-PD-1 alone (nivolumab or pembrolizumab): Fewer side effects; frequently preferred in older patients or those with comorbidities. More than a third are alive at 10 years.
- Subcutaneous administration: Subcutaneous forms of nivolumab (December 2024) and pembrolizumab (September 2025) were approved in the United States, shortening treatment time.
Immunotherapy side effects (such as inflammation of the bowel, liver, thyroid, lungs or skin) can usually be controlled when recognized early. We explain their management in immunotherapy side effects . A new trial: in a phase 3 study announced in May 2026, another LAG-3 inhibitor (fianlimab) combined with cemiplimab failed to meet its primary endpoint against first-line pembrolizumab.
BRAF-Mutant Melanoma: Which Treatment Should Come First?
Approximately half of melanoma patients have a BRAF gene mutation in the tumor. Combining BRAF and MEK inhibitors (dabrafenib + trametinib, vemurafenib + cobimetinib, encorafenib + binimetinib) produces rapid tumor shrinkage in a high proportion; however, most responses eventually end as resistance develops.
In DREAMseq, which addressed the question of treatment sequence, 2-year survival in patients starting with nivolumab + ipilimumab was 71,8%, compared with those starting dabrafenib + trametinib, in whom it was 51,5% . Consequently, immunotherapy is now generally preferred first in patients with BRAF mutations as well; targeted therapy takes priority when a rapid response is needed, symptoms are severe or the disease progresses quickly. We discuss this in detail in starting with immunotherapy in BRAF-positive melanoma .
Brain Metastases
Brain metastasis used to be considered melanoma's worst prognostic factor. In CheckMate 204, among patients with asymptomatic brain metastases receiving nivolumab + ipilimumab, the intracranial tumor shrinkage rate was 53,5%, and 3-year survival was 71,9% . Outcomes in symptomatic brain metastases (such as seizures or headache) were more limited: 3-year survival was 36,6%. Radiotherapy and surgery also play important roles in these patients. For details, see our article on treatment of brain metastases in melanoma .
New Options After Immunotherapy
Immune cells from the patient's surgically removed tumor are expanded in the laboratory and returned to the patient. After anti-PD-1 therapy, response rates are approximately 31%; median response duration is 36,5 months and 5-year survival is 19,7%. FDA approval: February 2024.
A genetically modified virus injected directly into the tumor to stimulate the immune system. In the group evaluated by the FDA, the response rate was 24,2% and median response duration 14,1 months. After two rejection letters, it received accelerated approval in August 2026.
New combinations, cell therapies and vaccines are being investigated. Patients who do not respond to standard treatments should be evaluated for suitable trials.
Resectable Advanced Disease: Immunotherapy First
In advanced melanoma (stage 3 or limited stage 4) that can be completely removed surgically, starting immunotherapy before surgery is an important innovation. In SWOG S1801, 2-year event-free survival in patients receiving preoperative and postoperative pembrolizumab was 72%, compared with 49% in those receiving pembrolizumab only after surgery. We discuss this in this article . In August 2026, the first positive phase 3 result was announced for personalized mRNA vaccine intismeran plus pembrolizumab, reducing recurrence risk in resected high-risk melanoma; detailed data have not yet been published.
Melanoma arising from the eye's internal structures (uveal melanoma) differs biologically from skin melanoma and responds less well to most treatments effective in skin melanoma. Specific treatments, such as tebentafusp approved in 2022, have been developed for these patients. This article's statistics concern skin melanoma. We discuss ocular melanoma in a separate article .
- Do not get stuck on old statistics: Figures still circulating online, such as "5-year survival in stage 4 melanoma is 10-25%," come from the pre-immunotherapy era.
- Study figures concern selected patients: The 43% 10-year survival was achieved in patients in good general condition who qualified for the trial. Real-world results may be lower.
- Different studies cannot be compared: Nivolumab + ipilimumab and nivolumab + relatlimab have not been directly compared in any study.
- Effectiveness and side effects must be weighed together: The most effective combination also has the most serious side effects; the choice must consider age, comorbidities and patient preferences.
- Treatment can be stopped in long-term responders: Stopping immunotherapy after a certain period in patients with good responses is being investigated and is increasingly common in practice; this decision must be made with the oncologist.
The Situation in Türkiye
- Incidence: According to 2024 estimates published by the International Agency for Research on Cancer in July 2026, approximately 1.716 new melanoma cases are diagnosed annually in Türkiye, with 664 melanoma deaths. Approximately 6.300 people diagnosed within the last 5 years are living with melanoma.
- Immunotherapy: Nivolumab, pembrolizumab and ipilimumab are on the SGK reimbursement list. According to summaries on drug-price websites, nivolumab is reimbursed alone or with ipilimumab as first-line treatment in patients in good general condition (ECOG 0-1); ipilimumab is limited to a maximum of 4 doses; switching to another immunotherapy after progression on one is generally not reimbursed.
- Targeted therapy: Dabrafenib (alone or with trametinib) and vemurafenib + cobimetinib appear to be reimbursed for BRAF V600-mutant patients without prior BRAF inhibitor use; switching between BRAF/MEK drugs is not reimbursed. We discuss the status of encorafenib and binimetinib in our Braftovi and Mektovi articles.
- New treatments: We could not find information indicating that lifileucel (TIL) or RP1 is licensed in Türkiye.
- Reimbursement conditions change frequently, so the current situation should be confirmed with your oncologist and hospital pharmacy. We summarize the general SGK conditions for immunotherapies in this article .
Symptoms and Follow-Up
The most important warning sign of melanoma is a new mole or a change in an existing mole's color, shape, size or surface. Bleeding, crusting or ulceration also require attention. Advanced disease may cause swollen, hard lymph nodes, unexplained weight loss, shortness of breath, bone pain, headache or neurological symptoms. We illustrate differences between normal moles and melanoma in our skin cancer photographs article. We discuss the risk in people with a family history in familial melanoma .
Patients receiving or completing treatment for advanced melanoma are generally followed in the early years with examinations and imaging (CT, PET-CT or brain MR) every 3-6 months. The oncologist determines the frequency according to disease status, treatment and time. All melanoma patients should continue annual skin examinations and protect themselves from the sun.
Frequently Asked Questions
- What Is the Life Expectancy With Stage 4 Melanoma?
- There is no single figure. United States population data show 34% 5-year relative survival in melanoma with distant spread. In selected patients receiving dual immunotherapy, median survival is approximately 6 years and 43% are alive after 10 years. Individual outcomes depend on disease extent, LDH, brain metastases, general condition and treatment response.
- Can Stage 4 Melanoma Be Completely Cured?
- For some patients, yes. In complete or long-term responders to immunotherapy, disease can remain controlled for years; in CheckMate 067, 96% of those progression-free at year 3 had not died from melanoma at year 10. The term "functional cure" is increasingly used for these patients.
- I Have a BRAF Mutation. Which Treatment Should I Start With?
- Studies showed longer survival when patients in good general condition started with immunotherapy. However, BRAF/MEK inhibitors may take priority in rapidly progressing disease or when a rapid response is needed. The decision must be made with your oncologist.
- Can Melanoma That Has Spread to the Brain Be Treated?
- Yes. With dual immunotherapy for asymptomatic brain metastases, more than half of patients had intracranial tumor shrinkage and 3-year survival was approximately 72%. Radiotherapy and surgery may also be part of treatment.
- Is Chemotherapy Used?
- Because chemotherapy has limited effectiveness in melanoma, it is now used only when immunotherapy and targeted treatments are exhausted or unsuitable.
- How Long Does Immunotherapy Last?
- It generally continues until disease progression or unacceptable side effects; in some patients it may be stopped within 1-2 years after a good response. The oncologist makes this decision individually.
- Does Melanoma Have a Worse Course During Pregnancy?
- Older studies reported a worse course for pregnancy-associated melanoma. However, a 2026 meta-analysis including only high-quality studies showed that, after accounting for stage, pregnancy did not independently worsen survival.
Glossary
- Melanocyte
- A cell producing melanin, the pigment that gives skin its color.
- Metastasis
- Spread of cancer from its original site to other parts of the body.
- 5-year relative survival
- The ratio of 5-year survival in cancer patients to that of the general population of the same age and sex.
- Melanoma-specific survival
- A survival measure counting only deaths due to melanoma.
- LDH
- Lactate dehydrogenase; elevated levels suggest more extensive and aggressive disease in advanced melanoma.
- Immune checkpoint inhibitor
- Drugs that release the brakes (CTLA-4, PD-1, LAG-3) preventing the immune system from attacking the tumor.
- BRAF/MEK inhibitor
- Oral targeted drugs that shut down the signaling pathway driving tumor growth in BRAF-mutant melanoma.
- TIL therapy
- Cell therapy in which immune cells within the tumor are expanded in the laboratory and returned to the patient.
- Oncolytic virus
- A genetically modified virus that multiplies inside tumor cells, destroys them and stimulates the immune system.
- Neoadjuvant treatment
- Treatment given before surgery.
DROZDOGAN Academy Commentary
Metastatic melanoma has undergone the greatest transformation in oncology over the past 15 years. We have moved from an era when median survival was under a year to one in which a substantial proportion are alive after 10 years.
⚡ Why It Matters
Patients diagnosed with metastatic melanoma and their families still encounter outdated, pessimistic statistics online. Current data show that this disease can now be controlled for long periods in many patients; accurate information directly influences treatment decisions and hope.
✅ Strengths
10-year data from two major phase 3 studies demonstrate that long-term responses are real. A randomized trial addressed treatment sequencing in BRAF-mutant patients. New options after immunotherapy, such as cell therapy and oncolytic viruses, have been approved. Preoperative immunotherapy and personalized vaccines are also transforming early disease.
⚠️ Limitations
Long-term survival data come from selected trial patients. Approximately half do not benefit sufficiently from initial immunotherapy, and options remain limited for this group. Serious side effects of dual immunotherapy are important. New treatments (TIL, RP1) are unavailable in Türkiye and very expensive.
🩺 What to Do in Practice
- At diagnosis, make sure the tumor has undergone BRAF testing .
- Make treatment decisions with a medical oncology team experienced in melanoma, and with a tumor board if possible.
- During immunotherapy, report new symptoms such as diarrhea, shortness of breath, jaundice or extreme fatigue without delay.
- Ask whether brain MR imaging is included in follow-up to assess brain metastases.
- When standard treatments do not work, explore clinical trial options.
❓ Open Questions
What is the best strategy for patients who do not respond to initial immunotherapy? Which patients can safely stop treatment? Will personalized mRNA vaccines also be effective in advanced disease? Will preoperative immunotherapy become standard in limited metastatic disease?
Our Brief Verdict: Stage 4 melanoma is far more treatable today than 10-15 years ago. Population data show 5-year survival of approximately one-third; with the most effective treatment, around half of selected patients are alive after 10 years, and in the vast majority of long-term responders the disease does not become a problem again. Old statistics do not reflect this reality.
- This article is the September 2026 update of a piece published on our website in 2019. It was prepared using publicly accessible sources (SEER, the American Cancer Society, AJCC staging summaries, FDA announcements, company statements, professional news sources, IARC and drug-price websites in Türkiye). The full texts of the primary journal articles (NEJM, Lancet Oncology, JCO) could not be accessed.
- Removed or corrected from the previous version: 2019 SEER data were updated; older stage-specific survival rates were replaced with AJCC 8 data; the statement "5-year survival in stage 4 is 10-25%" was corrected using current data; unverifiable survival rates by lymph node count and oligometastasis rates were removed; the statement "17% higher mortality" in pregnancy-associated melanoma was replaced with the finding of the 2026 meta-analysis; drug spelling errors were corrected, and encorafenib + binimetinib, nivolumab + relatlimab, TIL therapy and RP1 were added.
- Based on general knowledge: Approval dates in the 2011-2022 timeline, the number of patients underlying AJCC 8, the side-effect comparison of nivolumab + relatlimab with nivolumab + ipilimumab, the ranking of brain metastasis frequency and follow-up recommendations are presented as established oncology knowledge.
- Not verified: The 5-year survival rate of RELATIVITY-047; licensing status of Opdualag, lifileucel and RP1 in Türkiye; the full SUT text of melanoma reimbursement conditions (reimbursement information was taken from summaries on drug-price websites).
- "Our assessment" and the Academy commentary are our own.
- The diagrams were derived from verified statements in the text and contain no new data.
- This article is not personal medical advice. Treatment decisions should be made together with your oncologist.
Sources
- National Cancer Institute SEER. Cancer Stat Facts: Melanoma of the Skin (2016-2022 data).
- American Cancer Society. Key statistics for melanoma skin cancer, 2026.
- Gershenwald JE et al. Melanoma staging: evidence-based changes in the AJCC eighth edition. CA Cancer J Clin. 2017 (via summaries from Melanoma Institute Australia and the Skin Cancer Foundation).
- Wolchok JD et al. CheckMate 067, 10-year results. N Engl J Med. September 15, 2024. OncLive and BMS statements.
- Merck. KEYNOTE-006 10-year results, ESMO 2024 (LBA44).
- Robert C et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626-636. ASCO Post summary.
- Tawbi HA et al. RELATIVITY-047 5-year update. ASCO 2026, abstract 9532.
- Atkins MB et al. DREAMseq. J Clin Oncol. October 2022. ASCO Post summary.
- Tawbi HA et al. CheckMate 204 final analysis. Lancet Oncol. 2021. ASCO Post summary.
- FDA. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. February 16, 2024. Targeted Oncology: C-144-01 5-year results, June 2025.
- FDA. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. August 6, 2026. Dermatology Times.
- Patel SP et al. SWOG S1801. N Engl J Med. 2023. ASCO Post and Targeted Oncology summaries.
- Merck and Moderna. INTerpath-001 phase 3 results. Press release, August 19, 2026.
- Regeneron. Fianlimab + cemiplimab phase 3 update. May 15, 2026.
- FDA. Nivolumab and hyaluronidase subcutaneous (December 27, 2024); pembrolizumab and berahyaluronidase alfa subcutaneous (September 19, 2025).
- OncLive. Immunotherapy combinations reign supreme in upfront melanoma management. February 28, 2025.
- Stylianakis et al. Pregnancy-associated melanoma: meta-analysis. Crit Rev Oncol Hematol. 2026.
- International Agency for Research on Cancer. Türkiye fact sheet, GLOBOCAN 2024 estimates. July 2026.
- ilacfiyati.com and ilacabak.com: Opdivo, Keytruda, Yervoy, Tafinlar, Cotellic and Braftovi pages. September 2026.
Sources
The American Cancer Society medical and editorial content team - Last Medical Review: May 19, 2016 - Last Revised: February 1, 2019.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.